Antiviral / immunomodulator

Inosine pranobex

Brand names: Imunovir

Inosine pranobex is an orally administered antiviral and immunomodulatory agent used for mucocutaneous herpes simplex infections and, in specialist settings, subacute sclerosing panencephalitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is thought to act by enhancing host cell-mediated immune responses and impairing viral replication, giving combined antiviral and immunostimulant effects.

Prescribing in practice

Because it raises serum and urinary uric acid, it should be used with caution in patients with gout, hyperuricaemia or a history of urolithiasis.
Use with caution in renal impairment, where uric acid handling is reduced.
Evidence of clinical benefit is limited, so it is generally reserved for selected indications rather than first-line use.

Monitoring

Monitor serum uric acid and renal function during prolonged or repeated courses, particularly in those predisposed to gout or stones.

Counselling the patient

Maintain a good fluid intake while taking this medicine.
Report joint pain, swelling or loin pain that could suggest gout or kidney stones.
Take the medicine for the full course as directed even if symptoms settle.

Evidence & guidelines

Its place in therapy is limited; consult the SPC and current prescribing references for licensed indications and cautions.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways